W
WAVEMAN · COMPANY
ANIP · Ani Pharmaceuticals Inc
> Ask across nine datasets ⌘K
LIVE
TEAM-0.32% 13F +439META+2.47% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV+4.49% 13F +693CRM+2.92% 13F +1,018CVNA-0.98% 13F +794TPL-0.71% 13F +444NET-4.47% 13F +710MSTR-1.35% 13F +526DELL+4.91% 13F +1,203CRWD+5.68% 13F +1,382ANET+1.22% 13F +1,323COIN+10.14% 13F +475TEAM-0.32% 13F +439META+2.47% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV+4.49% 13F +693CRM+2.92% 13F +1,018CVNA-0.98% 13F +794TPL-0.71% 13F +444NET-4.47% 13F +710MSTR-1.35% 13F +526DELL+4.91% 13F +1,203CRWD+5.68% 13F +1,382ANET+1.22% 13F +1,323COIN+10.14% 13F +475
← ALL COMPANIES

ANIP

ANI PHARMACEUTICALS INC
PHARMA & BIOTECH · PHARMACEUTICAL PREPARATIONS · CIK 0001023024
FORM 144 · 3☆ WATCH
INSIDER NET · 180D
-$9.1M
open-market buys minus sells, Form 4 codes P and S
INSIDER BUYERS · 180D
0
CONGRESS BUYERS · 1Y
0
FUNDS ADDED · QTR
178
13F, latest reported quarter
REVENUE GROWTH
+43.8%
XBRL, annual
NET MARGIN
8.9%
CONVERSIONS · 180D
2
codes C/M, not in net · $328.0K priced
SEVEN FACTS, RANKED AGAINST THE SECTOR · RANK IS NOT A FORECAST
INSIDERS
net -$9.1M over 180 days
-$1.9M over 90 days
below 84% of Pharma & Biotech
CONGRESS
no member of Congress has reported trading it
FUNDS
178 funds added or opened last quarter
more than 84% of Pharma & Biotech
REVENUE
+43.8% year over year
more than 77% of Pharma & Biotech
MARGIN
8.9% net margin
more than 80% of Pharma & Biotech
BUYBACKS
$20.6M repurchased, FY to 2026-06-30
below 62% of Pharma & Biotech
SHORT
9.2 days to cover · settled 2026-07-31
THE SITUATION · EVERY LINE IS ONE RULE OVER ONE DATASET
Insiders are net sellers: -$9.1M across 9 people in 180 days.
178 funds added or opened positions in the latest 13F quarter, of 311 holders.
The year, with the filings on it
Total return indexed to 100 over the last 12 months · every marker is a federal filing, placed at its date — hover any marker for the detail
TOTAL 12M RETURN -24.3%
-24.3%12M
-25%-15%-5%+5%2025-092025-102025-122026-032026-052026-072026-09 2026-05-11 · Lalwani Nikhil sold $4.3M2025-11-12 · Gassert Chad sold $1.3M2026-05-13 · Walsh Patrick D sold $806.3K2025-11-13 · Walsh Patrick D sold $750.9K2025-09-03 · Pera Antonio R sold $692.3K2026-02-12 · Mutz Christopher sold $538.3K2026-03-03 · Walsh Patrick D sold $445.4K2026-02-20 · Mutz Christopher sold $415.3K2026-08-25 · Lalwani Nikhil sold $401.2K2026-03-09 · Davis Krista sold $377.1K2026-03-11 · Rowland Thomas Andrew sold $357.5K2026-05-11 · Walsh Patrick D sold $320.8K2026-03-05 · CAREY STEPHEN P. sold $302.2K2026-07-02 · CAREY STEPHEN P. sold $284.9K2026-03-09 · Mutz Christopher sold $267.2K2026-06-05 · CAREY STEPHEN P. sold $265.0K2026-03-05 · CAREY STEPHEN P. sold $249.8K2026-08-10 · Gutwerg Ori sold $243.5K2026-06-29 · CAREY STEPHEN P. sold $239.7K2026-07-29 · CAREY STEPHEN P. sold $231.9K2026-03-13 · Mutz Christopher sold $226.5K2026-05-12 · Gutwerg Ori sold $220.4K2026-08-31 · CAREY STEPHEN P. sold $207.5K2026-06-08 · HAUGHEY THOMAS sold $161.8K2026-02-19 · Davis Krista sold $161.6K2026-03-03 · Gutwerg Ori sold $157.6K2026-03-06 · Mutz Christopher sold $157.4K2025-12-05 · TANNENBAUM RENEE P sold $146.1K2026-02-20 · Davis Krista sold $134.9K2025-12-18 · Davis Krista sold $133.7K2026-03-06 · Davis Krista sold $111.4K2025-09-19 · Davis Krista sold $98.0K2026-01-13 · Cook Meredith sold $42.2K2026-06-12 · Cook Meredith sold $41.0K2026-07-13 · Cook Meredith sold $40.9K2025-09-12 · Cook Meredith sold $39.4K2026-05-13 · Cook Meredith sold $39.1K2026-04-13 · Cook Meredith sold $39.0K2026-02-13 · Cook Meredith sold $38.4K2026-08-13 · Cook Meredith sold $37.7K2026-05-12 · Rowland Thomas Andrew sold $36.4K2026-03-13 · Cook Meredith sold $36.3K2026-08-25 · NIKHIL LALWANI filed to sell $400.5K2026-07-29 · STEPHEN P CAREY filed to sell $499.4K2026-07-07 · PATRICK WALSH filed to sell $373.7K
INSIDER SELLFORM 144
INDEXED RETURN, DIVIDEND-ADJUSTED — NOT A PRICE CHART · LARGE TRADES DRAWN FIRST WHEN A NAME FILES HEAVILY
Live price
Daily candles from TradingView, on their licence — no filings are marked on this one
WHY THIS NAME IS ON THE DESK
Insiders have filed to sell — before selling.
The record shows a net $9.1M sold by insiders over 180 days, 178 funds added last quarter, $1.3M in planned Form 144 sales. Every figure is a federal filing, dated the day it became public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector from the SEC's own SIC classification
UTHRCPIXMRNAREGNLLYALNYELFCITRMDGLDNAVRTXNUVL
Insider transactions
Form 4 purchases and sales (codes P and S) — grants, option exercises and preferred conversions excluded

Over the last 180 days, ANI PHARMACEUTICALS INC insiders sold a net $9.1M of stock across 204 Form 4 purchases and sales, with 0 insider(s) buying. Source: SEC Form 4 filings, as of 2026-09-05.

INSIDER
FILED
SHARES
VALUE
CAREY STEPHEN P.
SVP & CFO
SELL
2026-08-31
2,850.0
$207.5K
Lalwani Nikhil
PRESIDENT & CEO
SELL
2026-08-25
5,400.0
$401.2K
Cook Meredith
SR. VP, GENERAL COUNSEL & SEC.
SELL
2026-08-13
500.0
$37.7K
Gutwerg Ori
SVP, GENERICS
SELL
2026-08-10
3,162.0
$243.5K
CAREY STEPHEN P.
SVP & CFO
SELL
2026-07-29
2,850.0
$231.9K
204 TRANSACTIONS ON RECORD

Showing the most recent few. Create a free account to see 199 more transactions on record, the cross-source screener and CSV export. We store only your email address, and there is no password to create.

Institutional holders
13F · holdings as of the latest quarter funds have reported
BlackRock, Inc.
2,958,646.0 sh
$244.9M
Soleus Capital Management, L.P.
867,760.0 sh
$71.8M
VANGUARD CAPITAL MANAGEMENT LLC
838,224.0 sh
$69.4M
STATE STREET CORP
831,647.0 sh
$68.9M
TANG CAPITAL MANAGEMENT LLC
707,500.0 sh
$58.6M
SCHEDULE 13D/G
No 5%+ ownership filings
Nobody has crossed 5% with a filing obligation. Absence is a fact here, not missing data.
Planned sales · Form 144
Filed before the sale — intent, not a trade
NIKHIL LALWANI
FILED 2026-08-25
$400.5K
STEPHEN P CAREY
FILED 2026-07-29
$499.4K
PATRICK WALSH
FILED 2026-07-07
$373.7K
Fund concentration
N-PORT · funds ranked by how much of THEMSELVES they put in this stock — the conviction number 13F cannot show
Invesco Pharmaceuticals ETF
$10.1M POSITION · AS OF 2026-04-30
3.0%
Ranger Micro Cap Fund
$282.8K POSITION · AS OF 2026-04-30
2.4%
TETON Convertible Securities Fund
$248.6K POSITION · AS OF 2026-03-31
2.2%
abrdn Focused U.S. Small Cap Active ETF
$210.9K POSITION · AS OF 2026-04-30
2.1%
State Street(R) SPDR(R) S&P(R) Pharmaceuticals ETF
$6.0M POSITION · AS OF 2026-03-31
1.9%
PROFUND VP PHARMACEUTICALS
$188.8K POSITION · AS OF 2026-03-31
1.9%
SEC N-PORT, MONTHLY WITH A ~60-DAY PUBLIC LAG · FUNDS ≥ $10M · % = SHARE OF THE FUND'S OWN BOOK
Fundamentals
Annual figures from XBRL filings · pick a past date to see them exactly as the market knew them then — restatements and all
2025-122024-122023-122022-12
REVENUE$883.4M$614.4M$486.8M$316.4M
OPERATING INCOME$111.1M$584.0K$47.0M$-35.3M
NET INCOME$78.0M$-19.0M$19.0M$-48.0M
EPS (DILUTED)3.32-1.040.85-3.05
OPERATING CASH FLOW$185.2M$64.0M$119.0M$-31.2M
CASH$285.6M$144.9M$221.1M$48.2M
LONG-TERM DEBT$291.8M$309.1M$284.8M$285.7M
BUYBACKS$12.2M$11.0M$5.0M$2.0M
DIVIDENDS PAID$1.2M$1.6M$1.6M$1.6M
SEC XBRL · FISCAL-YEAR PERIODS · AS KNOWN ON 2026-09-05 · NOBODY ELSE SHOWS FUNDAMENTALS AS OF A PAST DATE
W WAVEMAN

Public filings, honestly analyzed. Official US government sources in one desk — every figure carries the date it was filed, and the methodology is published, backtest included.

SEC FORM 4FORM 13F 13D/GFORM 144XBRL STOCK ACTCONTRACTSFEC CFPBNRC
PRODUCT
DeskBacktester CompaniesAccount
SUPPORT
FAQMethodology Contact
LEGAL
TermsPrivacy Accessibility
© 2026 WAVEMAN · SOURCE: SEC EDGAR & OFFICIAL GOVERNMENT DATA · NOT INVESTMENT ADVICE · CHART BY TRADINGVIEW · UPDATED 2026-09-05 ALL SYSTEMS LIVE FOR MACHINES →